Sinovac Biotech Faces Financial Downturn in 2024
Sinovac's 2024 revenue drops amidst market challenges, with ongoing vaccine development and international market expansions.
- Latest
- Trending
Sinovac's 2024 revenue drops amidst market challenges, with ongoing vaccine development and international market expansions.
Orora declines Lone Star's $2.25B bid, citing undervaluation. Offer was 33.9% premium to last stock close.
Ethereum rebounds post-crash with bullish outlook, targeting $3,000 amid market recalibration and investor optimism.
China Yuchai sees 12.4% sales growth, 32.8% surge in engine sales. Strategic investments boost future prospects.
Cryptocurrency markets slip as Bitcoin and Ethereum react to CPI data, indicating a risk-off sentiment among investors.
Crypto venture funding rises to $2.7B in Q2 2024, despite a 12.5% drop in deal numbers and ETF inflows plunging ...
Appian partners with OSTech to improve business efficiency by 25% using automation and digital transformation services.
iCAD's Q2 revenue increased by 21% as the company shifts to a cloud-based SaaS model, aiming for enhanced profitability.
Dogecoin's price surges 18% in a week, influenced by market trends and speculation about potential X platform integration.
Bitcoin price drops to $58k as Mt Gox test transactions and USDT outflows raise concerns, offsetting CPI cheer.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.